Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster

被引:34
|
作者
Wilhelm, Ilca Ricarda [1 ]
Tzabazis, Alexander [1 ]
Likar, Rudolf [2 ]
Sittl, Reinhard [1 ]
Griessinger, Norbert [1 ]
机构
[1] Univ Hosp Erlangen, Dept Anaesthesiol, D-91054 Erlangen, Germany
[2] Landeskrankenhaus Klagenfurt, Dept Anaesthesiol & Intens Care, Klagenfurt, Austria
关键词
central regional pain syndromes; lidocaine; lidoderm; local anaesthetics; peripheral nervous system diseases; postherpetic neuralgia; POSTHERPETIC NEURALGIA; PATCH; 5-PERCENT; DOUBLE-BLIND; EFFICACY; TOLERABILITY; RELIEVES; SCALE;
D O I
10.1097/EJA.0b013e328330e989
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background and objective The 5% lidocaine medicated plaster is a topical treatment for peripheral neuropathic pain symptoms (e.g. burning, shooting and stabbing pain) and is registered for the treatment of postherpetic neuralgia. This study examined the efficacy and tolerability of long-term treatment with the 5% lidocaine medicated plaster in patients with localized neuropathic pain conditions. Methods Twenty patients with localized neuropathic pain [postoperative neuropathic pain (n = 14); complex regional pain syndrome (n = 2); and postherpetic neuralgia (n = 4)], who had been successfully treated with 5% lidocaine medicated plaster, were followed up by telephone interview after 3 and 5 years. Questions were related to the efficacy, development of tolerance, tolerability, wear time and comfort of the plaster. Results At 3 years, 10 out of 20 (50%) initial responders were still using the plasters with no decline in analgesic efficacy. After 5 years, eight of the original 20 responders (40%) maintained treatment and continued to experience effective pain relief. The 12 responders who discontinued treatment did so because they no longer required analgesic therapy (n = 4); their health insurer refused to fund treatment (n = 2); they were lost to follow-up (n = 1); or had died from an illness unrelated to plaster treatment (n = 5). No patient discontinued because of inadequate analgesia or intolerable side effects. Reversible erythema occurred in two patients wearing the plaster for more than 16 h. There were no systemic side effects. Conclusion The 5% lidocaine medicated plaster provides sustained pain relief over long-term treatment in patients with neuropathic pain of various causes and is well tolerated. Eur J Anaesthesiol 27:169-173 (c) 2010 European Society of Anaesthesiology.
引用
收藏
页码:169 / 173
页数:5
相关论文
共 50 条
  • [41] Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
    Schimrigk, Sebastian
    Marziniak, Martin
    Neubauer, Christine
    Kugler, Eva Maria
    Werner, Gudrun
    Abramov-Sommariva, Dimitri
    EUROPEAN NEUROLOGY, 2017, 78 (5-6) : 320 - 329
  • [42] Treatment of Neuropathic Pain with the Capsaicin 8% Patch: Is Pretreatment with Lidocaine Necessary?
    Kern, Kai-Uwe
    Nowack, Walburga
    Poole, Chris
    PAIN PRACTICE, 2014, 14 (02) : E42 - E50
  • [43] 5% Lidocaine Medicated Plaster in Elderly Patients with Postherpetic Neuralgia Results of a Compassionate Use Programme in France
    Clere, Florentin
    Delorme-Morin, Claire
    George, Brigitte
    Navez, Malou
    Rioult, Bruno
    Tiberghien-Chatelain, Florence
    Ganry, Herve
    DRUGS & AGING, 2011, 28 (09) : 693 - 702
  • [44] Cost Effectiveness of a Lidocaine 5% Medicated Plaster Compared with Pregabalin for the Treatment of Postherpetic Neuralgia in the UKA Markov Model Analysis
    Mark Ritchie
    Hiltrud Liedgens
    Mark Nuijten
    Clinical Drug Investigation, 2010, 30 : 71 - 87
  • [45] 5% Lidocaine Medicated Plaster in Elderly Patients with Postherpetic NeuralgiaResults of a Compassionate Use Programme in France
    Florentin Clère
    Claire Delorme-Morin
    Brigitte George
    Malou Navez
    Bruno Rioult
    Florence Tiberghien-Chatelain
    Hervé Ganry
    Drugs & Aging, 2011, 28 : 693 - 702
  • [46] Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland
    Smith, Amelia
    Doran, Stephen
    Daly, Maria
    Kennedy, Cormac
    Barry, Michael
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (01) : 133 - 140
  • [47] Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom
    Dakin, Helen
    Nuijten, Mark
    Liedgens, Hiltrud
    Nautrup, Barbara Poulsen
    CLINICAL THERAPEUTICS, 2007, 29 (07) : 1491 - 1507
  • [48] Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy Subjects
    Gudin, Jeffrey
    Webster, Lynn R.
    Greuber, Emileigh
    Vought, Kip
    Patel, Kalpana
    Kuritzky, Louis
    JOURNAL OF PAIN RESEARCH, 2021, 14 : 513 - 526
  • [49] Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study
    Demant, Dyveke T.
    Lund, Karen
    Finnerup, Nanna B.
    Vollert, Jan
    Maier, Christoph
    Segerdahl, Martha S.
    Jensen, Troels S.
    Sindrup, Soren H.
    PAIN, 2015, 156 (11) : 2234 - 2244
  • [50] Cost-effectiveness analysis of 5% lidocaine-medicated plaster compared with pregabalin for the treatment of post-herpetic neuralgia in China
    Zeng, Fei
    Wang, Meng
    Zhang, Daying
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (04) : 4493 - +